A line's name is a label on a stock, not a description of a biology. Most of the arguments that end a paper's review start with a line being treated as the normal tissue it came from: a spontaneously immortalised keratinocyte carrying an aneuploid genome and a mutant tumour suppressor is not normal skin, and it was never meant to be. This page says what the commonly ordered designations are models of, where each one departs from the tissue, and which of them are not immortalised lines at all.
Human iPSC cell lines are not immortalised lines, and behave differently
An induced pluripotent stock is a self-renewing but karyotypically normal population that has to be differentiated before it models anything, and the differentiated product is the experiment rather than the stock. Two consequences follow and both are routinely missed: the derivative is usually immature relative to adult tissue, so a physiological parameter measured in it sits closer to fetal than adult values; and the line carries its donor's genome, so a phenotype can be the donor rather than the manipulation. Compare against an isogenic control from the same donor wherever the claim depends on genotype.
What a HuH7 cell line is a model of, and what it is not
A hepatocellular carcinoma line that retains more liver-specific function than most, which is why it is used where a hepatocyte-like cell is needed and a primary hepatocyte is impractical. It is not a hepatocyte: drug-metabolising enzyme expression is far below primary tissue and varies with passage and confluence, so induction work done in it does not transfer quantitatively. Treat it as a tractable liver-derived background, and state the comparison you are not making.
An A2780 cell line and the resistant derivatives sold beside it
An ovarian carcinoma line whose value is largely that platinum-resistant sublines were derived from it, so sensitive and resistant pairs exist on one background. That is exactly where identity discipline matters most: the pairs differ by selection history, several distinct derivatives share similar names, and the resistance phenotype drifts if the selective agent is withdrawn for long. Record which derivative and where it came from, and re-verify the resistance rather than assuming it survived the freezer.
A human myoblast cell line and a human fibroblast cell line: mostly primary, sometimes immortalised
Both of these are usually sold as primary cells with a finite number of divisions, or as the same cells immortalised by forced telomerase expression. The distinction changes the experiment rather than the price: a primary stock has a window in which it behaves, and an immortalised one has a genome that has been intervened in and a proliferation control that no longer applies. Myoblasts add a second constraint, because their usefulness depends on still being able to fuse, and that capacity falls with passage well before the cells stop dividing.
An MCF7 cell line and a U251 cell line are not interchangeable backgrounds
The first is a hormone-receptor-positive breast carcinoma line and is the standard background for oestrogen-responsive work, which also makes it sensitive to phenol red and to the serum lot. The second is a glioblastoma line with a documented identity problem: stocks circulating under closely related designations have been shown to be the same or cross-contaminated, which is why short tandem repeat verification on receipt is not optional for it. Neither substitutes for the other, and a result that only exists in one background is a result about that background.
A human cardiomyocyte cell line, and what differentiation leaves behind
There is no immortalised adult human cardiomyocyte in general use, so what is sold under this description is almost always a stem-cell-derived preparation. The cells beat, express the right markers and are genuinely useful, and they remain immature: the electrophysiology, the metabolism and the structural organisation sit short of adult myocardium, and maturation protocols narrow the gap rather than close it. Report the preparation and its age, because both change the numbers.
HUVEC and A375 stocks, and what primary origin costs
Umbilical vein endothelial cells are primary, finite and donor-specific, so lot variation is part of the measurement rather than noise around it; pooled lots hide it and single-donor lots let you see it. The melanoma line beside them is immortalised and carries a well-known activating kinase mutation, which is the reason it is chosen and the reason a result in it is about that mutation's background. In both cases the honest method section names the lot, the passage and the medium, because all three move the answer.
Questions people ask about hacat cell line
Does a line's name tell me its genotype?
No. It tells you a stock's identity at best, and even that only if the stock was verified. Short tandem repeat profiling on receipt and again at publication is the check, and for lines with documented cross-contamination histories it is the difference between a result and a retraction.
Which of these are not really cell lines?
The primary stocks: endothelial cells, most fibroblast and myoblast preparations unless they say otherwise, and anything stem-cell-derived. They have a finite window, donor identity and lot variation, and they should be described by lot and passage rather than by name alone.
Can I substitute one line for another from the same tissue?
Only if the claim does not depend on the background, which is rarely the case. Lines from one tissue differ in receptor status, driver mutation and differentiation state, so a substitution is a new experiment and should be reported as one.